3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Sarcoma
1
Resectable Esophageal Cancer
1
Pleural Mesothelial Neoplasm
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Melanoma
1
Hematologic Neoplasms
1
Colorectal Neoplasms
1
Interventions
pembrolizumab
141
Nivolumab
117
Ipilimumab
69
Cyclophosphamide
34
Specimen Handling
30
Magnetic Resonance Spectroscopy
28
trametinib
23
fludarabine
22
binimetinib
22
Interleukin-2
21
dabrafenib
19
relatlimab
17
encorafenib
17
Biopsy
17
aldesleukin
16
CTLA-4 Antigen
16
fludarabine phosphate
15
cemiplimab
15
atezolizumab
15
Radiosurgery
15
Opdualag
14
Radiotherapy
11
lifileucel
10
lenvatinib
10
Blood Specimen Collection
10
spartalizumab
8
Paclitaxel
8
Cisplatin
8
Bevacizumab
8
cobimetinib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Adjuvants, Immunologic
×
1 year
×
Clear all
NCT04594187
2026-02-17
MelPORT
M.D. Anderson Cancer Center
Phase 2
Recruiting
168 enrolled